SAS and Carolina partner to accelerate antiviral drug development

Posted Nov 19, 2021
SAS, a leader in analytics and software services, and the University of North Carolina are teaming up to transform the drug development process to prevent infectious disease threats from turning into a pandemic like COVID-19. The partnership is focused on the work of the University’s Rapidly Emerging Antiviral Drug Development Initiative (READDI). (UNC.edu)

Related: Campus Connections

Pantry Bowl 2025 combats campus hunger
UNC and NC State will again come together on something both can agree on — making sure no student goes to class hungry. The fifth...
Tue Nov 25, 2025

How UNC superfan, Randall Keen, rallies in Carolina blue
Living with ALS hasn’t stopped 64-year-old Randall Keen from cheering for nearly every Tar Heel team — or from teaching his daughter, Avery, what it...
Tue Nov 25, 2025

UNC honors murdered student body president Eve Carson on 40th birthday
Eve Carson is frozen in time as the bubbly, beloved UNC student body President. A bright future was cut short in 2008, when she was...
Sun Nov 23, 2025

Another Record-High Graduation Success Rate For UNC Student-Athletes
For the sixth consecutive year, UNC student-athletes established a record-high multi-year graduation rate as reported in the NCAA's annual Graduation Success Rates. The overall student-athlete...
Fri Nov 21, 2025